Drugs / Agrippal
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01682369 | Sep 2012 → Feb 2013 | influenza | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT01636102 | Jul 2012 | influenza | Novartis Vaccines | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT01310400 | Oct 2009 → Jan 2010 | influenza | Crucell Holland BV | Completed | No outcome recorded |
| Phase 3 | NCT00841763 | Oct 2008 → Apr 2009 | influenza | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00464672 | Apr → Jul 2007 | influenza | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00310648 | Jan 2006 → ? | influenza | Novartis | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00560066 | Nov 2007 → Jul 2008 | influenza | Novartis Vaccines | Completed | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03893669 Comparator | Sep → Oct 2012 | — | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03826719 Comparator | Feb → Mar 2014 | influenza | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03704740 Comparator | Oct 2018 → Jul 2019 | influenza | SK Bioscience Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02686398 Comparator | Oct 2013 → Nov 2014 | end stage renal failure, influenza | Korea University Guro Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01771367 Comparator | Jan → Jun 2013 | — | University of Surrey | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Agrippal | “A Phase II Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Agrippal®), Formulation 2012/2013” NCT01636102 ↗11“a primarily European-marketed trivalent vaccine (Agrippal®, Novartis Vaccines), and a predominantly U.S.-marketed control trivalent vaccine (Fluvirin®, Novartis Vaccines)” PMID 22691101 ↗ Jun 2012 “Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture (Optaflu®) or in Embryonated Hen Eggs (Agrippal®)” NCT00560066 ↗ “initial dose of a licensed, non-adjuvanted, trivalent, seasonal influenza vaccine (Agrippal(®)) on Day 1” PMID 22192847 ↗ Dec 2011 “a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal, Novartis Vaccines)” PMID 18289372 ↗ Feb 2008 “Administer a dose of 0.25ml of vaccine TIV (Agrippal)” NCT01682369 ↗ |
| Modality | Vaccine | “a non-adjuvanted subunit influenza vaccine (Subunit; Agrippal, Novartis Vaccines)” PMID 18289372 ↗ Feb 2008 |
| Route | Intramuscular | “Adolescents and adults received one dose of vaccine intramuscularly, whereas children aged 3-8 years received two vaccine doses, administered 4 wk apart” PMID 22691101 ↗ Jun 2012 |